Co-tron board again welcome stoopharmaceutical enterprises: the first half of the net loss of more than 300 million, the market value of 37 billion yuan.

"
Pharmaceutical Network Industry Dynamic" June 22, the company ushered in a biopharmaceutical enterprise - Beijing Shenzhou Cell Biotechnology Group Co., Ltd("Shenzhou Cell")The issue price of Shenzhou cell is 25.64 yuan per share, the opening price of 85 yuan / share, the market value of 37.04 billion yuanthis Shenzhou cell landing branch board is the fifth set of listing standardsAccording to data disclosed in the prospectus, Shenzhou Cells' revenue for 2017, 2018 and 2019 was RMB599.27 million, RMB2.9457 million and RMB2.6383 million, respectivelyDuring the reporting period, Shenzhou cells generate revenue mainly related to sales of commodities, equipment leasing and housing rental and other businessAccording to the issuer's preliminary estimates, operating income is expected to be rmb 160,000 to RMB170,000 in January-June 2020, down 90.61 percent to 91.16 percent year-on-yearthe company has been losing money in terms of net profitFor fy2017, FY 2018 and 2019, the net profit attributable to the parent company's common shareholders was RMB14,127.96 million, RMB45,325.82 million and -79,47, respectivelyNet profit attributable to common shareholders of the parent company, net of non-recurring gains and losses, was RMB20,556.61 million, RMB32,054.69 million and RMB66,015.49 million, respectivelyIn addition, in January-June 2020, it is expected that the net loss attributable to shareholders of the parent company will be approximately RMB307.61 million to RMB32.417 million, a decrease of 10.415 million yuan to RMB12.71 million in the same period last year
however, in recent years, Shenzhou Cells has continued to invest a large amount of money in pre-clinical research and clinical trials of product pipelinesAccording to the prospectus, the Company's research and development expenses for FY2017, 2018 and 2019 were RMB189 million, RMB435 million and RMB516 million, respectively currently rich in research and development product pipeline of Shenzhou cells, and has strong ability in clinical drug screening, functional verification and development of biological drugs Of the company's 23 drug development pipelines, 21 are innovative drugs and 2 are biosimilars with high clinical needs All varieties are independent research and development of the company, with commercial rights and interests on a global scale At the same time, the company has the ability to develop and develop technology industrialization, 7 varieties have been issued by the Beijing Food and Drug Administration "drug production license." data show that Shenzhou Cell was founded in 2007, is an innovative biopharmaceutical research and development company dedicated to the development of biological drugs with differentiated competitive advantages, focusing on monoclonal antibodies, recombinant proteins and vaccines and other biological drug products research and development and industrialization This time the company listed on the company board, the sponsor is CICC Previously, the company has been Qihua II, Qiming Rongcheng, HanFuyuan, DingYu Fu Ran and other companies to invest industry pointed out that in recent years, with the introduction of a new drug evaluation system, the adjustment of domestic drug structure, as well as the capital market to the innovation of pharmaceutical companies, promote the new drug field into a golden period of rapid development the biopharmaceutical market for Shenzhou cells is growing rapidly, according to the consulting firm Frost and Sullivan The global biopharmaceutical market is expected to grow to $402.1 billion in 2018 and is expected to grow at a CAGR of nearly 9.0% With economic growth and the increase in the prevalence of chronic diseases, the domestic biopharmaceutical market will increase from 262.2 billion yuan in 2018 to 641.2 billion yuan in 2023, with a CAGR of nearly 19.6% In the context of the rapid growth of the biopharmaceutical market, many biopharmaceutical companies are scrambling to lay out Among them, there is no shortage of pharmaceutical companies listed with the help of The Company According to incomplete statistics, as of June 12, the number of biopharmaceutical enterprises has reached 26, including 15 enterprises with a market value of more than 10 billion, including Huaxi Bio, Nan Micromedicine, Bai Otai, Microcore Bio.